NCT06701201View on ClinicalTrials.gov

A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Enrolling by invitationOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

February 28, 2042

Study Completion Date

February 28, 2042

Conditions
Cancer
Interventions
DRUG

SynKIR-110

Autologous T cells Transduced with Mesothelin KIR-CAR

DRUG

SynKIR-310

Autologous T Cells transduced with CD19 KIR-CAR

Trial Locations (5)

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

53792

University of Wisconsin Carbone Cancer Center, Madison

66205

University of Kansas Cancer Center, Westwood

77030

MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, part of Sarah Cannon Research Institute, Denver

Sponsors
All Listed Sponsors
lead

Verismo Therapeutics

INDUSTRY

NCT06701201 - A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product | Biotech Hunter | Biotech Hunter